Vor Biopharma (NYSE:VOR) Price Target Cut to $13.00 by Analysts at HC Wainwright

Vor Biopharma (NYSE:VOR - Get Free Report) had its price objective reduced by research analysts at HC Wainwright from $17.50 to $13.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock.

A number of other analysts have also weighed in on the company. JMP Securities restated a "market outperform" rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Stifel Nicolaus lowered their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research report on Friday. Finally, Wedbush reiterated an "outperform" rating and set a $7.00 target price on shares of Vor Biopharma in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $8.86.

Vor Biopharma Trading Down 4.2 %

NYSE VOR traded down $0.04 during trading hours on Friday, reaching $0.85. 166,281 shares of the company's stock were exchanged, compared to its average volume of 591,618. The firm has a fifty day moving average of $1.20 and a 200-day moving average of $1.01. Vor Biopharma has a one year low of $0.63 and a one year high of $2.43. The stock has a market cap of $58.19 million, a PE ratio of -0.51 and a beta of -0.40.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VOR. Two Sigma Investments LP increased its holdings in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the last quarter. Northern Trust Corp increased its stake in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares during the last quarter. Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at approximately $102,000. RA Capital Management L.P. raised its holdings in Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the 4th quarter valued at $80,000. Institutional investors and hedge funds own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.